These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 22407777)

  • 1. Vaccine process technology.
    Josefsberg JO; Buckland B
    Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technologies that make administration of vaccines safer.
    Clements CJ; Larsen G; Jodar L
    Vaccine; 2004 May; 22(15-16):2054-8. PubMed ID: 15121322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative vaccine production technologies: the evolution and value of vaccine production technologies.
    Bae K; Choi J; Jang Y; Ahn S; Hur B
    Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
    Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
    Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review on current downstream bio-processing technology of vaccine products.
    Li M; Qiu YX
    Vaccine; 2013 Feb; 31(9):1264-7. PubMed ID: 23313813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines.
    Middelberg AP; Rivera-Hernandez T; Wibowo N; Lua LH; Fan Y; Magor G; Chang C; Chuan YP; Good MF; Batzloff MR
    Vaccine; 2011 Sep; 29(41):7154-62. PubMed ID: 21651936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature.
    Mrsny RJ
    J Drug Target; 1998; 6(4):243-9. PubMed ID: 9894692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies.
    Brennan FR; Dougan G
    Vaccine; 2005 May; 23(24):3210-22. PubMed ID: 15837222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.
    Hegde NR
    Hum Vaccin Immunother; 2015; 11(5):1223-34. PubMed ID: 25875691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants].
    Koprowski H
    Arch Immunol Ther Exp (Warsz); 2002; 50(6):365-9. PubMed ID: 12549429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of marker vaccine and differential diagnostic test technology.
    Henderson LM
    Biologicals; 2005 Dec; 33(4):203-9. PubMed ID: 16257545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insect cell technology is a versatile and robust vaccine manufacturing platform.
    Mena JA; Kamen AA
    Expert Rev Vaccines; 2011 Jul; 10(7):1063-81. PubMed ID: 21806400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases.
    Kaslow DC
    Trans R Soc Trop Med Hyg; 2004 Oct; 98(10):593-601. PubMed ID: 15289096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus vaccines in plants.
    Giorgi C; Franconi R; Rybicki EP
    Expert Rev Vaccines; 2010 Aug; 9(8):913-24. PubMed ID: 20673013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Can modern vaccine technology pursue the success of traditional vaccine manufacturing?
    Grabherr R; Reichl U
    Biotechnol J; 2015 May; 10(5):657-8. PubMed ID: 25943526
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative high throughput analytics to support polysaccharide production process development.
    Noyes A; Godavarti R; Titchener-Hooker N; Coffman J; Mukhopadhyay T
    Vaccine; 2014 May; 32(24):2819-28. PubMed ID: 24576849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.